199 related articles for article (PubMed ID: 23455868)
1. Dabigatran etexilate: management in acute ischemic stroke.
Javedani PP; Horowitz BZ; Clark WM; Lutsep HL
Am J Crit Care; 2013 Mar; 22(2):169-76. PubMed ID: 23455868
[TBL] [Abstract][Full Text] [Related]
2. Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
Bissig D; Manjunath R; Traylor BR; Richman DP; Ng KL
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):e102-e104. PubMed ID: 28416406
[TBL] [Abstract][Full Text] [Related]
3. Rash associated with dabigatran etexilate.
To K; Reynolds C; Spinler SA
Pharmacotherapy; 2013 Mar; 33(3):e23-7. PubMed ID: 23400964
[TBL] [Abstract][Full Text] [Related]
4. Hemopericardium in a patient treated with dabigatran etexilate.
Barton CA; McMillian WD; Raza SS; Keller RE
Pharmacotherapy; 2012 May; 32(5):e103-7. PubMed ID: 22488474
[TBL] [Abstract][Full Text] [Related]
5. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
7. Intravenous thrombolysis in a stroke patient taking dabigatran.
Lee VH; Conners JJ; Prabhakaran S
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):916.e11-2. PubMed ID: 22608344
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
10. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
Roskell NS; Lip GY; Noack H; Clemens A; Plumb JM
Thromb Haemost; 2010 Dec; 104(6):1106-15. PubMed ID: 20967400
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
Brunetti L; Chen C; White J
Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
[TBL] [Abstract][Full Text] [Related]
12. Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization.
Sangha N; El Khoury R; Misra V; Lopez G
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):917.e5-8. PubMed ID: 22683118
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran in clinical practice.
Nagarakanti R; Ellis CR
Clin Ther; 2012 Oct; 34(10):2051-60. PubMed ID: 23031622
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.
Ezekowitz MD; Connolly S; Parekh A; Reilly PA; Varrone J; Wang S; Oldgren J; Themeles E; Wallentin L; Yusuf S
Am Heart J; 2009 May; 157(5):805-10, 810.e1-2. PubMed ID: 19376304
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
Huisman MV; Lip GY; Diener HC; Brueckmann M; van Ryn J; Clemens A
Thromb Haemost; 2012 May; 107(5):838-47. PubMed ID: 22318514
[TBL] [Abstract][Full Text] [Related]
16. Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment.
Watanabe M; Siddiqui FM; Qureshi AI
Neurocrit Care; 2012 Feb; 16(1):203-9. PubMed ID: 21748501
[TBL] [Abstract][Full Text] [Related]
17. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
Paikin JS; Haroun MJ; Eikelboom JW
Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
[TBL] [Abstract][Full Text] [Related]
18. New options with dabigatran etexilate in anticoagulant therapy.
Maegdefessel L; Spin JM; Azuma J; Tsao PS
Vasc Health Risk Manag; 2010 May; 6():339-49. PubMed ID: 20531953
[TBL] [Abstract][Full Text] [Related]
19. Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Wilcox R; Pendleton RC; Smock KJ; Rodgers GM
Hosp Pract (1995); 2011 Aug; 39(3):23-34. PubMed ID: 21881389
[TBL] [Abstract][Full Text] [Related]
20. Management of dabigatran-associated intracerebral and intraventricular hemorrhage: a case report.
Faust AC; Peterson EJ
J Emerg Med; 2014 Apr; 46(4):525-9. PubMed ID: 24508114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]